No Prescription |
 |
 | ||
|
Cosopt Eye Drops GB Generic Dorzolamide Timolol |
|
| ||
No Prescription » Prescription Drugs 5 » Cosopt Eye Drops GB Generic Dorzolamide Timolol This product contains two drugs used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (e.g. ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers and dorzolamide belongs to a class of drugs known as carbonic anhydrase inhibitors. Buy Cosopt Eye Drops GB Generic Dorzolamide Timolol and other Prescription Drugs 5 products online at Medstore. Buy Online at Medstore - Click Here!
About Cosopt Eye Drops GB Generic Dorzolamide Timolol: Product Type: Prescription Drugs 5 Cosopt Eye Drops(GB) ( Generic Dorzolamide & Timolol ) Product Origin: United Kingdom Cosopt Eye Drops (GB Generic Dorzolamide & Timolol) GB Generic Dorzolamide & Timolol 2%/0.5% 15mL 5mL GB Generic Dorzolamide & Timolol Cosopt Eye Drops
View more Prescription Drugs 5 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
